A detailed history of Royal Bank Of Canada transactions in Belite Bio, Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 5 shares of BLTE stock, worth $338. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5
Holding current value
$338
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$46.52 - $83.84 $232 - $419
5 New
5 $0
Q1 2023

May 15, 2023

BUY
$25.61 - $33.5 $2,407 - $3,149
94 New
94 $2,000

Others Institutions Holding BLTE

About BELITE BIO, INC


  • Ticker BLTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,867,400
  • Market Cap $1.68B
  • Description
  • Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...
More about BLTE
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.